The global systemic lupus erythematosus (SLE) drugs market is anticipated to grow at a considerable CAGR of 7.1% during the forecast period (2022-2028). The continuous involvement of pharmaceutical and biotechnology companies in drugs development is acting as one of the prime factors impacting the growth of the market. Additionally, the high unmet need for current treatment and developments in healthcare technology will also increase the growth rate of the market. Furthermore, the rise in the research and development activities, launch of effective therapies, and emerging new markets will provide beneficial opportunities for the SLE drugs market. For instance, in February 2022, AstraZeneca’s Saphnelo (anifrolumab) had received approval from the European Union for the purpose of providing treatment to adult patients with moderate to severe active autoantibody-positive systemic lupus erythematosus (SLE), in spite of obtaining standard therapy.
However, the lack of infrastructure in low-income countries and the high cost associated with the treatment will impede the growth rate of the market. Additionally, less awareness and complications involved with the disease will further challenge the growth of the SLE drugs market in the forecast period.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- including Astra Zeneca PLC, GlaxoSmithkline plc, ImmuPharma PLC, Johnson and Johnson Pvt. Ltd., Pfizer Inc., and others
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Systemic Lupus Erythematosus (SLE) Drugs Market Report Segment
By Treatment Types
By Mode of Delivery
Global Systemic Lupus Erythematosus (SLE) Drugs Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World